Abstract
Introduction . Early diagnosis of oncological diseases is one of the most important tasks of public health, because improves the quality of medical care for patients and the prognosis of the disease. Despite advances in oncology, pediatric tumors continue to be diagnosed at advanced stages, which may be associated with a delayed visit to a doctor and a delay in diagnosis due to several factors. Many foreign articles are devoted to the search and analysis of significant factors of untimely diagnosis of oncological diseases, but few similar works in Russia. Purpose of the study – to identify factors of late diagnosis and treatment of children with retinal tumors using the example of a common childhood tumor of retinoblastoma (RB). Material and methods . A retrospective cohort study of patients diagnosed with RB at the of the Research Institute of Pediatric Oncology and Hematology at N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia (Research Institute of Pediatric Oncology and Hematology) was performed using the database of the hospital cancer registry. The study group included RB patients from Russia with a first diagnosis in the period from 2016 to 2019 and receiving treatment at the Research Institute of Pediatric Oncology and Hematology. Time intervals were calculated based on the dates of the first symptom of RB, the initial medical consultation, the date of the final diagnosis by an oncologist or ophthalmologist, and the date of the first therapy for a child with RB. The intervals were calculated in days. Results . Data from 197 patients (aged 0 to 15 years) were analyzed, which corresponded to 262 cases and the number of eyes with bilateral or unilateral Rb. The median diagnostic interval for patients with localized RB (groups A and B) was 30 days, for patients with locally advanced RB (groups C, D and E) 41 days. The median treatment initiation interval for localized and locally advanced RB was 15 days. Age (p = 0.0067) and patient gender were statistically significantly correlated with the diagnostic interval. For strabismus, the median diagnostic interval was 91 days (p < 0.0001), and when RB was detected during a preventive medical examination, the median diagnostic interval was 17 days (p < 0.0001). The event-free survival of the eyes depended on the prevalence of the process (in groups A, B, C) and the duration of the doctors’ interval (p = 0.0394). The distance to the cancer center was not statistically significant. Conclusion . Predictors of late diagnosis and initiation of treatment in our study: gender, age of the patient at the time of diagnosis, and the first specific symptom of RB.
Highlights
Diagnosis of oncological diseases is one of the most important tasks of public health, because improves the quality of medical care for patients and the prognosis of the disease
Pediatric tumors continue to be diagnosed at advanced stages, which may be associated with a delayed visit to a doctor and a delay in diagnosis due to several factors
Many foreign articles are devoted to the search and analysis of significant factors of untimely diagnosis of oncological diseases, but few similar works in Russia
Summary
Ретроспективное когортное исследование пациентов с диагнозом РБ в НИИ детской онкологии и гематологии ФГБУ «НМИЦ онкологии им. Блохина» Минздрава России (НИИ ДОиГ) было выполнено с использованием базы данных детского госпитального канцер-регистра. Медиана (Me) диагностического интервала для больных с локализованной РБ (группы А и В) составила 30 дней, для пациентов с местно-распространенной РБ (группы С, Д и Е) – 41 день. Me интервала начала лечения для локализованной и местно-распространенной РБ была 15 дней. Которые мы рассматривали как предикторы поздней диагностики и начала лечения, только пол, возраст пациента на момент постановки диагноза и первый специфичный симптом РБ оказались значимыми в нашем исследовании. Для цитирования: Малахова А.А., Михайлова С.Н., Ушакова Т.Л., Поляков В.Г. Аналитический обзор организационно-методического отдела НИИ детской онкологии и гематологии ФГБУ «НМИЦ онкологии им. Pirogov Russian National Research Medical University, Ministry of Health of Russia; 1 Ostrovityanova St., Moscow, 117997, Russia
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Russian Journal of Pediatric Hematology and Oncology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.